VOLITIONRX LTD 8-K

What Happened

• VolitionRx Ltd (VNRX) filed an 8‑K on April 23, 2026 disclosing a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard from the NYSE American.
• In accordance with NYSE American procedures, the company issued a press release on April 23, 2026 discussing the matters disclosed in the notice (Exhibit 99.1 to the 8‑K).
• The filing reiterates forward‑looking statements and notes the company’s expectation regarding regaining compliance with the NYSE American’s continued listing standards.

Key Details

• Filing date: April 23, 2026 (Current Report on Form 8‑K).
• Press release: Exhibit 99.1 dated April 23, 2026.
• Compliance deadline referenced in the filing: August 6, 2027 (the date by which the company expects to regain compliance).
• The company warns that inability to regain compliance could materially and adversely affect results of operations and the stock price.

Why It Matters

• A delisting or noncompliance notice from NYSE American puts VolitionRx’s continued listing at risk, which can reduce liquidity and market visibility for retail investors.
• The company has a defined period to cure the deficiency (through August 6, 2027 as noted), but there is no guarantee of success; the filing highlights material risks and potential adverse impacts on the stock price.
• Investors should review the company’s press release (Exhibit 99.1) and recent SEC filings (10‑Q/10‑K) for details on the issues cited and any remediation plans before making investment decisions.